(0.20%) 5 191.27 points
(0.31%) 38 973 points
(0.06%) 16 359 points
(-0.74%) $77.90
(0.96%) $2.22
(-0.18%) $2 326.90
(0.21%) $27.67
(2.38%) $987.85
(-0.05%) $0.928
(0.44%) $10.87
(0.09%) $0.797
(0.27%) $91.59
Live Chart Being Loaded With Signals
NightHawk Biosciences, Inc., an integrated biopharmaceutical company, engages in the development of immune therapies and vaccines. The company's therapies are used to modulate the immune system against various diseases, including cancer and infectious diseases...
Stats | |
---|---|
本日の出来高 | 161 222 |
平均出来高 | 163 739 |
時価総額 | 10.78M |
EPS | $0 ( 2024-03-29 ) |
次の収益日 | ( $0 ) 2024-05-13 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.202 |
ATR14 | $0.0430 (13.71%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2022-12-07 | Wolf Jeffrey Alan | Buy | 2 843 137 | Stock Option (right to buy) |
2022-12-07 | Smith Edward B Iii | Buy | 101 960 | Stock Option (right to buy) |
2022-12-07 | Prendergast John K A | Buy | 203 921 | Stock Option (right to buy) |
2022-12-07 | Ostrander William L. | Buy | 490 196 | Stock Option (right to buy) |
2022-12-07 | Monahan John J | Buy | 101 960 | Stock Option (right to buy) |
INSIDER POWER |
---|
100.00 |
Last 95 transactions |
Buy: 24 129 486 | Sell: 659 541 |
ボリューム 相関
NightHawk Biosciences, 相関
10 最も正の相関 |
---|
10 最も負の相関 |
---|
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
NightHawk Biosciences, 相関 - 通貨/商品
NightHawk Biosciences, 財務諸表
Annual | 2022 |
収益: | $5.98M |
総利益: | $-420 025 (-7.02 %) |
EPS: | $-1.710 |
FY | 2022 |
収益: | $5.98M |
総利益: | $-420 025 (-7.02 %) |
EPS: | $-1.710 |
FY | 2021 |
収益: | $2.11M |
総利益: | $0.00 (0.00 %) |
EPS: | $-1.410 |
FY | 2020 |
収益: | $2.95M |
総利益: | $0.00 (0.00 %) |
EPS: | $-1.630 |
Financial Reports:
No articles found.
NightHawk Biosciences,
NightHawk Biosciences, Inc., an integrated biopharmaceutical company, engages in the development of immune therapies and vaccines. The company's therapies are used to modulate the immune system against various diseases, including cancer and infectious diseases. Its gp96 platform, including ImPACT, an allogenic cell-based, T-cell-stimulating platform that functions as an immune activator to stimulate and expand T-cells; and ComPACT, which delivers antigen driven T-cell activation and specific co-stimulation in a single product. The company develops HS-110, which has completed enrollment in a Phase II clinical trial to treat patients with advanced non-small cell lung cancer; and HS-130 that is in Phase I clinical trial for the treatment of advanced solid tumors. Its products also include PTX-35, a novel T-cell co-stimulator agonist antibody targeting DR3/TNFRSF25 that is in Phase I clinical trial; DR3/TNFRSF25 for various immunotherapy approaches; and COVID-19 vaccine, which is in preclinical stage. The company has a collaboration with Dr. James Shapiro at University of Alberta to manufacture surrogate mouse version of PTX-35. The company was formerly known as Heat Biologics, Inc. and changed its name to NightHawk Biosciences, Inc. in May 2022. NightHawk Biosciences, Inc. was incorporated in 2008 and is headquartered in Morrisville, North Carolina.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。